Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-1.39% $2.13
America/New_York / 17 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 13.80 mill |
EPS: | -3.57 |
P/E: | -0.600 |
Earnings Date: | May 13, 2024 |
SharesOutstanding: | 6.48 mill |
Avg Daily Volume: | 0.139 mill |
RATING 2024-04-17 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Neutral | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.600 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.10x |
Company: PE -0.600 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.397 (-81.38%) $-1.733 |
Date: 2024-04-18 |
Expected Trading Range (DAY) |
---|
$ 1.932 - 2.35 ( +/- 9.72%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Werner Milton H. | Buy | 45 000 | Stock Option (right to buy) |
2024-04-01 | Lees-rolfe Garth | Buy | 90 000 | Stock Option (right to buy) |
2024-04-01 | Lees-rolfe Garth | Sell | 5 834 | Stock Option (right to buy) |
2023-06-30 | Berman Dennis N | Buy | 6 667 | Stock Option (right to buy) |
2023-06-30 | Dion Gisele | Buy | 6 667 | Stock Option (right to buy) |
INSIDER POWER |
---|
96.60 |
Last 62 transactions |
Buy: 1 923 769 | Sell: 2 120 717 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.13 (-1.39% ) |
Volume | 0.0370 mill |
Avg. Vol. | 0.139 mill |
% of Avg. Vol | 26.55 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Date | Signal | @ |
---|---|---|
MPCC.OL | Apr 18 - 03:08 | NOK13.31 |
TOM.OL | Apr 18 - 03:08 | NOK144.70 |
SOFF.OL | Apr 18 - 03:08 | NOK41.32 |
IDEX.OL | Apr 18 - 03:04 | NOK2.01 |
SHLF.OL | Apr 18 - 03:05 | NOK19.62 |
ENSU.OL | Apr 18 - 03:04 | 1.154 |
SCHA.OL | Apr 18 - 03:03 | NOK307.60 |
2020.OL | Apr 18 - 03:02 | NOK151.50 |
RTYUSD | Apr 18 - 03:07 | 1 969.70 |
FLNG.OL | Apr 18 - 03:00 | NOK280.00 |